All In Biotech

Drug Trial Radar · NCT00471497

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 846 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

846

Actual

Start

Jul 31, 2007

Primary completion

Sep 2, 2009

Study completion Aug 21, 2019

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
May 10, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP). An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.

Conditions

  • Myelogenous Leukemia, Chronic

Interventions

  • nilotinibDrug

    Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.

  • imatinibDrug

    Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With ImputationTime frame: Baseline, 12 months
  2. Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With ImputationTime frame: 12 months

Locations

213 sites in 35 countries. Site status is shown where the registry gives one.

  • University of California at Los Angeles Dept. of Hematology Clinic

    Los Angeles, California

  • Kaiser Permanente - California Southern Dept of Kaiser South 3

    San Diego, California

  • Kaiser Permanente - California Northern Vallejo Med Center/Med Offices

    Vallejo, California

  • Kaiser Permanente - California Northern Kaiser Med

    Vallejo, California

  • Rocky Mountain Cancer Centers RMCC - Colorado Springs

    Greenwood Village, Colorado

  • Florida Cancer Specialists Dept. FloridaCancerSpecialists

    Fort Myers, Florida

  • Advanced Medical Specialties Research Dept.

    Miami, Florida

  • Cancer Centers of Florida PA Cancer Centers of FL

    Ocoee, Florida

  • Florida Retina Institute Flordia Cancer Affilates

    Orlando, Florida

  • University of Chicago Section of Hematology/Oncology

    Chicago, Illinois

  • Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow

    Beech Grove, Indiana

  • University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics

    Iowa City, Iowa

  • Kansas City Cancer Center KCCC Business Office

    Overland Park, Kansas

  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center

    New Orleans, Louisiana

  • Michigan State University / Breslin Cancer Center Breslin Cancer Center

    Lansing, Michigan

  • Missouri Cancer Associates Dept. of Boone Hospital Center

    Columbia, Missouri

  • Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants

    St Louis, Missouri

  • Hackensack University Medical Center Department of Research

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center Clinical Trials Office

    New York, New York

  • University of North Carolina UNC Lineberger Cancer Center

    Chapel Hill, North Carolina

  • Wake Forest University Health Sciences Dept. of Industry Research

    Winston-Salem, North Carolina

  • University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.

    Cincinnati, Ohio

  • Cleveland Clinic Foundation CCF

    Cleveland, Ohio

  • Northwest Cancer Specialists Compass Oncology -BKM

    Portland, Oregon

  • Cancer Centers of the Carolinas CC of C -Eastside

    Greenville, South Carolina

  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology

    Chattanooga, Tennessee

  • Tennessee Oncology Dept. of Centennial Medical

    Nashville, Tennessee

  • Texas Cancer Center ( Medical City Dallas Hospital)

    Dallas, Texas

  • Cancer Care Centers of South Texas HOAST CCC of So.TX- Medical Center

    San Antonio, Texas

  • Tyler Cancer Center

    Tyler, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Charleroi, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Yvoir, Belgium

Showing 40 of 213 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.